Aclarion closed a $10.4 million common‐stock financing priced at $5.18 per share, bolstering its balance sheet with zero debt and $21.6 million in cash as of January 12, 2026. This equity‐only raise extends the company’s operating runway into 2028 under current plans, preserves capital structure integrity, and provides strategic flexibility to support upcoming clinical and commercial milestones for its Nociscan AI platform.

The company will accelerate patient enrollment in its CLARITY trial, targeting approximately 25% of patients enrolled by the end of Q2 2026, with an internal analysis planned after the first cohort’s three-month follow-up. Aclarion also aims to complete and publish multiple investigator-led real-world evidence studies, broaden Nociscan compatibility across leading MRI platforms to increase its addressable market by over 30%, and launch version 2.8 of the software in Q1 2026. Concurrently, the company is engaging with several U.S. commercial payers to advance broader reimbursement coverage.

In 2025, annual Nociscan scan volumes rose 69% year-over-year, with fourth-quarter volumes up 114% versus the prior year across U.S., U.K. and European sites. Despite these strong adoption trends, Aclarion’s shares declined 5.21% to trade at a new 52-week low on Tuesday, reflecting short-term market pressure ahead of key trial readouts and reimbursement milestones.